RxDoctor Payments Data

Mohamed Koroma

Gerontology · Washington, DCNPI 1104211523

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 28 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 13 manufacturers, the largest accounting for just 23.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $299 and has fallen 72.6% since, to $82 in 2025.

$738in general payments, 2019–2025

Across 28 payments — averaging $26.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$177
  • Medtronic$147
  • Boston Scientific$109
  • Terumo Medical Corporation$46
  • Inari Medical, Inc.$42
  • Pfizer$38
  • plus $179 from 7 others

What the payments were for

  • Food & beverage$738100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

Too few gerontology providers in District of Columbiato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$117,589
Medicare patients
247
Services billed
1,283

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban15$7,961
Lacosamide29$2,227
Enoxaparin Sodium22$1,486
ClopidogrelClopidogrel Bisulfate31$377
Clonazepam16$280
Pregabalin14$197
Amlodipine Besylate14$132
Oxycodone Hcl17$106
Atorvastatin Calcium20$103
Tramadol Hcl11$88

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$38$7,96115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few gerontology providers in District of Columbiaon file to place this against a meaningful peer group, so we don't.

Other gerontology in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →